BlackRock Discloses 9.9% Stake in Dyne Therapeutics
Ticker: DYN · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1818794
| Field | Detail |
|---|---|
| Company | Dyne Therapeutics, INC. (DYN) |
| Form Type | SC 13G |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, stake-disclosure, investment-firm
TL;DR
**BlackRock just revealed a nearly 10% stake in Dyne Therapeutics, signaling big institutional confidence.**
AI Summary
BlackRock Inc., a major investment firm, reported on January 29, 2024, that it holds 5,745,466 shares of Dyne Therapeutics, Inc. common stock as of December 31, 2023. This represents a 9.9% ownership stake in Dyne Therapeutics. This matters to investors because BlackRock's significant stake indicates their confidence in Dyne Therapeutics' future, potentially signaling a positive outlook for the stock.
Why It Matters
BlackRock's substantial investment in Dyne Therapeutics could be seen as a vote of confidence, potentially attracting other investors and influencing the stock's performance.
Risk Assessment
Risk Level: low — This filing indicates a large institutional investor has a significant stake, which generally adds stability rather than risk.
Analyst Insight
A smart investor would view BlackRock's significant 9.9% stake as a positive signal, potentially indicating strong institutional confidence in Dyne Therapeutics, and might consider further research into the company's fundamentals and future prospects.
Key Numbers
- 5,745,466 — Shares Beneficially Owned (Represents the total number of Dyne Therapeutics shares BlackRock Inc. owns.)
- 9.9% — Ownership Percentage (Indicates BlackRock Inc.'s significant stake in Dyne Therapeutics, nearing a 10% threshold.)
- December 31, 2023 — Reporting Date (The specific date for which BlackRock's ownership stake is being reported.)
Key Players & Entities
- BlackRock Inc. (company) — reporting person and major investment firm
- Dyne Therapeutics, Inc. (company) — subject company whose stock is being reported
- 5,745,466 (dollar_amount) — number of shares beneficially owned by BlackRock Inc.
- 9.9% (dollar_amount) — percentage of class beneficially owned by BlackRock Inc.
- December 31, 2023 (person) — date of event requiring the filing
- January 29, 2024 (person) — filing date of the SC 13G
Forward-Looking Statements
- Other institutional investors may increase their positions in Dyne Therapeutics, Inc. (Dyne Therapeutics, Inc.) — medium confidence, target: Within 6 months
FAQ
What is the name of the company whose shares are being reported in this SC 13G filing?
The company whose shares are being reported is Dyne Therapeutics, Inc., as stated in the 'Name of Issuer' section of the filing.
Which entity filed this SC 13G report?
BlackRock, Inc. filed this SC 13G report, as indicated under 'Names of reporting persons' and in the 'FILED BY' section of the filing.
As of what date was the ownership stake reported in this filing accurate?
The ownership stake was accurate as of December 31, 2023, which is listed as the 'Date of Event Which Requires Filing of this Statement'.
What percentage of Dyne Therapeutics, Inc.'s common stock does BlackRock, Inc. beneficially own?
BlackRock, Inc. beneficially owns 9.9% of Dyne Therapeutics, Inc.'s common stock, as stated in the filing.
How many shares of Dyne Therapeutics, Inc. common stock does BlackRock, Inc. beneficially own?
BlackRock, Inc. beneficially owns 5,745,466 shares of Dyne Therapeutics, Inc. common stock, as detailed in the filing.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 by December 31, 2023 regarding Dyne Therapeutics, Inc. (DYN).